scispace - formally typeset
H

Helena Barrasa

Publications -  13
Citations -  454

Helena Barrasa is an academic researcher. The author has contributed to research in topics: Population & Pharmacodynamics. The author has an hindex of 6, co-authored 11 publications receiving 269 citations.

Papers
More filters
Journal ArticleDOI

Augmented Renal Clearance in Critically Ill Patients: A Systematic Review

TL;DR: Augmented renal clearance is a prevalent condition in critically ill patients, especially in young people, with urinary CrCl being the best diagnostic method because mathematical estimates tend to underestimate CrCl.
Journal ArticleDOI

Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.

TL;DR: ARC increases linezolid CL and leads to a high risk of underexposure with the standard dose, but an infusion rate of 75 mg/h should be considered to ensure C ≥‬2 2‬mg/mL, while continuous infusion increases the PTA.
Journal ArticleDOI

Population pharmacokinetics of daptomycin in critically ill patients.

TL;DR: The PK/PD analysis confirmed that 280- and 420-mg/d dosages would not be enough to achieve high probabilities of target attainment for MIC values ≥ 1 mg/L in patients with Clcr ≥ 60 mL/min or in subjects with lower Clcrs but receiving CRRT.
Journal ArticleDOI

Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

TL;DR: The standard dose (600mg q12h) ensures a moderately high probability of treatment success in anuric patients when the infection is due to microorganisms with MIC≤2mg/L; in patients with residual renal function, the standard dose is insufficient, but 900mg q8h provide higher probability of Treatment success without compromising the safety.